A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Allergan

Status: Completed

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02348476

GMA-SIM-14-024

Details and patient eligibility

About

This study is a retrospective chart review to assess the tolerability and efficacy of treatment with Simbrinza™ used for patients with Open-Angle Glaucoma or Ocular Hypertension.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants treated with Simbrinza™ for Intra-Ocular Pressure (IOP) lowering in at least one eye
• Participants who had at least one-follow-up visit with tolerablity and efficacy data after Simbrinza™ treatment initiation.

Exclusion criteria

• Active ocular disease other than glaucoma or ocular hypertension
• History of any intraocular surgery or glaucoma laser surgery within 3 months.

Trial design

150 participants in 1 patient group

Simbrinza™

Description:

Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.

Treatment:

Other: No Intervention